.jpeg)
2026-06-12 02:43:12
This article provides a comprehensive overview of vemurafenib (brand name Zelboraf), a targeted therapy for BRAF V600 mutation-positive melanoma. It covers standard dosage, administration instructions, dose adjustment principles, special population considerations, treatment monitoring requirements, and important safety information for patients and healthcare professionals.
2026-06-08 03:30:02
A comprehensive guide to the safety of Durvalumab (Imfinzi), detailing the identification, grading, and management of immune-related adverse events across multiple organ systems.
2026-06-08 03:18:47
Based on pivotal SPOTLIGHT and GLOW Phase III trials, this article analyzes the efficacy, durability of response, and real-world feedback of Zolbetuximab for advanced gastric cancer.
2026-06-08 03:13:03
A comprehensive guide to Mitotane resistance in ACC, covering its definition, mechanisms, and subsequent strategies including chemotherapy, targeted therapy, and clinical trial participation for patients and caregivers.
2026-06-08 02:54:25
Discover the latest 2026 data on Trametinib (Mekinist) plus Dabrafenib for BRAF V600-mutant tumors. This article covers efficacy, global cost insights, dosing, and side effect management for patients and caregivers worldwide.
2026-06-05 06:44:46
This article explains why mitotane, a drug for adrenocortical carcinoma, must not be stopped abruptly, and outlines a safe tapering protocol under medical supervision, including monitoring and management.
2026-06-05 06:17:52
Pemigatinib delivers breakthrough efficacy for patients with advanced cholangiocarcinoma harboring FGFR2 fusions/rearrangements, showing an objective response rate of 35.5% and a median overall survival of 21.1 months in a key study.
2026-06-05 06:10:25
Erlotinib is an oral EGFR tyrosine kinase inhibitor that works by precisely blocking the growth signaling pathways in non-small cell lung cancer cells harboring specific EGFR gene mutations, thereby inhibiting tumor progression.
2026-06-05 05:52:29
Tofacitinib is an oral JAK inhibitor that suppresses inflammation by blocking cytokine signaling pathways. It is approved for the treatment of various immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
2026-06-05 05:46:25
Tucatinib, a highly selective HER2 tyrosine kinase inhibitor, is demonstrating key value in treating HER2-positive breast cancer with brain metastases and colorectal cancer. Its precise mechanism and favorable tolerability are advancing HER2-targeted therapy.
2026-06-04 03:40:01
This article systematically explains the acquired resistance phenomenon of Garsorasib, a KRAS G12C covalent inhibitor, and details common resistance mechanisms, standardized diagnostic procedures, individualized subsequent treatment strategies based on different resistance mechanisms, cutting-edge combination regimens and clinical trial opportunities, providing comprehensive reference for clinical management and patient treatment decisions.
2026-06-03 03:11:10
This article provides a detailed analysis of the oral BRAF inhibitor vemurafenib, explaining its mechanism of action against the BRAF V600E mutation, its central role in treating advanced melanoma, its potential in other rare conditions like Erdheim-Chester disease, and outlines its standard usage and key safety considerations.
